Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of unplanned pregnancies
3.2.1.2 Increasing focus on women's reproductive rights
3.2.1.3 Advancements in medical technology
3.2.1.4 Increasing awareness and education
3.2.2 Industry pitfalls & challenges
3.2.2.1 Social and cultural stigma
3.2.2.2 High cost and side-effects associated with certain drugs
3.2.2.3 Stringent regulatory environment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Mifepristone
5.3 Misoprostol
5.4 Pitocin
5.5 Hemabate
5.6 Carboprost
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Hospital pharmacies
6.3 Retail pharmacies
6.4 Online pharmacies
Chapter 7 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East and Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Cipla Limited
8.2 Endo International plc
8.3 Exelgyn
8.4 Gedeon Richter plc
8.5 Jubilant Life Sciences
8.6 Lupin Limited
8.7 Mylan N.V.
8.8 Pfizer Inc.
8.9 Sun Pharmaceutical Industries
8.10 Torrent Pharmaceuticals Ltd.
8.11 Zydus Lifesciences Limited
